National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Childhood Hodgkin Lymphoma Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 08/14/2009



Purpose of This PDQ Summary






General Information






Cellular Classification and Biologic Correlates






Prognostic Factors in Childhood and Adolescent Hodgkin Lymphoma






Staging and Diagnostic Evaluation






Treatment Approach for Children and Adolescents with Hodgkin Lymphoma






Treatment of Primary Progressive/Recurrent Hodgkin Lymphoma in Children and Adolescents






Late Effects from Childhood/Adolescent Hodgkin Lymphoma Therapy






Get More Information From NCI







Changes to This Summary (08/14/2009)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Changes to This Summary (08/14/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Revised text to state that approximately 80% of childhood Hodgkin lymphoma cases with mixed-cellularity histology seen in developing countries are EBV positive (added Chabay et al. as reference 14).

Staging and Diagnostic Evaluation

Added Simpson et al. as reference 4.

Added Gallamini et al. as reference 13.

Treatment Approach for Children and Adolescents with Hodgkin Lymphoma

Added text to state that patients with nodular lymphocyte-predominant Hodgkin lymphoma are treated on risk-appropriate, classical Hodgkin lymphoma protocols.

Treatment of Primary Progressive/Recurrent Hodgkin Lymphoma in Children and Adolescents

Added Akhtar et al. as reference 16.

Added Schulz et al. as reference 24.

Late Effects from Childhood/Adolescent Hodgkin Lymphoma Therapy

Added Niinimäki et al. as reference 1.

Added text to state that the risk of secondary malignant neoplasm increases with radiation dose (cited Constine et al. as reference 62 and level of evidence 3iii).

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov